Recipient: Ludwig-Maximilians University of Munich Hospital
Funding: GO-Bio initial conceptual phase 4 (01/10/2023 to 30/09/2024, EUR 119,993.29)

Project description:

Increasing life expectancy throughout the world is leading to a rapid increase in chronic diseases such as dementia, which affects around 55 million people. This has serious consequences for those affected, their environment and health systems. In recent years there have been ground-breaking advances in the treatment of Alzheimer’s disease, the most common cause of dementia. New antibody drugs that are only effective in early stages are about to be approved. However, there is a lack of precise and scalable diagnostic procedures for effective use in routine care. The ki-alz data analytics platform is designed to help close this gap. The integration of diagnostic data, which is evaluated in combination with the help of artificial intelligence (AI), enables reliable and early diagnosis based on objective data. In the exploratory phase various possibilities for exploiting the project idea will be examined. Interviews and market analyses are carried out in order to identify potential customers and analyse the competitive situation. A patent strategy will be developed and an FTO analysis will be carried out to check the feasibility of the idea. In addition, the future composition of the team is planned. The unique and innovative approach to integrating and interpreting diagnostically significant data for Alzheimer’s disease using AI will create significant value for the healthcare system.